JBCHEPHARM - IntraDay Trade Analysis with Live Signals
Back to ListIntraDay Trade Rating: 4.2
| Stock Code | JBCHEPHARM | Market Cap | 34,104 Cr. | Current Price | 2,123 ₹ | High / Low | 2,177 ₹ |
| Stock P/E | 46.9 | Book Value | 238 ₹ | Dividend Yield | 0.73 % | ROCE | 25.9 % |
| ROE | 20.2 % | Face Value | 1.00 ₹ | DMA 50 | 1,982 ₹ | DMA 200 | 1,827 ₹ |
| Chg in FII Hold | -0.76 % | Chg in DII Hold | -0.12 % | PAT Qtr | 179 Cr. | PAT Prev Qtr | 200 Cr. |
| RSI | 64.8 | MACD | 47.2 | Volume | 4,35,699 | Avg Vol 1Wk | 5,47,625 |
| Low price | 1,303 ₹ | High price | 2,177 ₹ | PEG Ratio | 1.97 | Debt to equity | 0.01 |
| 52w Index | 93.9 % | Qtr Profit Var | 14.6 % | EPS | 46.5 ₹ | Industry PE | 27.6 |
📊 Analysis: JBCHEPHARM shows strong intraday momentum with RSI at 64.8 (bullish zone) and MACD at 47.2 (positive). Price is trading above both 50 DMA (1,982 ₹) and 200 DMA (1,827 ₹), indicating short-term strength. Volume is slightly below average, which reduces conviction, but fundamentals remain solid (ROE 20.2%, ROCE 25.9%). The stock is near its 52-week high (2,177 ₹), so upside may be capped intraday.
💰 Optimal Buy Price: 2,110–2,125 ₹ (near support, above 1,982 ₹ DMA).
🎯 Profit Exit Levels: 2,150 ₹ (first resistance), 2,175 ₹ (second resistance).
🛡️ Stop-Loss: 2,095 ₹ (below intraday support).
📈 If Already Holding: Exit near 2,150–2,175 ₹ if momentum indicators show continuation with strong volume. If price fails to sustain above 2,110 ₹, consider exiting to protect capital.
✅ Positive
- Strong ROCE (25.9%) and ROE (20.2%)
- Trading above 50 DMA and 200 DMA
- EPS at 46.5 ₹ supports earnings visibility
- Dividend yield at 0.73% provides income support
⚠️ Limitation
- Volume below average, reducing intraday conviction
- High P/E at 46.9 compared to industry PE of 27.6
- PEG ratio at 1.97, valuation concerns
📉 Company Negative News
- PAT declined slightly (179 Cr vs 200 Cr)
- FII holding decreased (-0.76%)
- DII holding decreased (-0.12%)
📈 Company Positive News
- Quarterly profit variation at +14.6%
- Strong 52-week index growth at 93.9%
🏭 Industry
- Industry PE at 27.6 vs JBCHEPHARM PE at 46.9 (stock appears overvalued)
- Pharma sector showing strong momentum and demand
🔎 Conclusion
JBCHEPHARM is fundamentally strong with bullish technical signals, but valuation is stretched and volume is slightly weak. Suitable for cautious intraday trades near support with strict stop-loss. Best for short scalps today, with potential upside toward resistance levels if momentum sustains.
Would you like me to extend this into a basket overlay with peers (Cipla, Sun Pharma, Divi’s Lab) so you can benchmark JBCHEPHARM’s intraday setup against sector leaders for confirmation signals?